Overall, these data suggest that IL-6R signaling regulates HNSCC stemness, and that combination therapy with Cisplatin and Tocilizumab prevents acquisition of the stem-like phenotype within HNSCC cells observed upon single-agent Cisplatin exposure. Here, IL6R is linked to head and neck squamous cell carcinoma.